Clearmind Medicine
CMND
1 hedge funds and large institutions have $260K invested in Clearmind Medicine in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 5 closing their positions.
90% more capital invested
Capital invested by funds: $137K → $260K (+$123K)
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
83% less funds holding
Funds holding: 6 → 1 (-5)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$349K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$61.7K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$35.2K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$10.2K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.96K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.35K |
CMND Hedge Fund Activity: Q4 2023 in Review
1 institutional investor reported a position in Clearmind Medicine (CMND) for Q4 2023, worth a combined $260K — up 90% from $137K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CMND and 0 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 1 added.
The largest buyer was AdvisorShares Investments, adding an estimated $349K. The largest seller was Walleye Capital, exiting entirely with an estimated $61.7K sold.
- 1 institutional investor held Clearmind Medicine (CMND) as of Q4 2023, down from 6 in Q3 2023.
- Funds reported $260K of Clearmind Medicine stock for Q4 2023, up 90% quarter-over-quarter.
- 0 funds opened new Clearmind Medicine positions in Q4 2023 and 5 closed out, a net change of -5 holders.
- The largest Clearmind Medicine buyer in Q4 2023 was AdvisorShares Investments, an estimated $349K added.
- The largest Clearmind Medicine seller in Q4 2023 was Walleye Capital, an estimated $61.7K sold.
Based on aggregated 13F filings for Q4 2023.